ABSTRACT

FDA Regulation of Cannabidiol (CBD) Consumer Products [Updated February 10, 2020]   [open pdf - 455KB]

From the Document: "Cannabidiol (CBD) is promoted as treatment for a range of conditions, including anxiety, pain, inflammation, and post-traumatic stress disorder--despite limited scientific evidence to substantiate or disprove many of these claims. CBD is derived from the 'Cannabis sativa' plant (commonly referred to as cannabis), which includes both marijuana and hemp. CBD and tetrahydrocannabinol (THC) are thought to be the most abundant cannabinoids in cannabis. CBD is considered to be nonpsychoactive and may be derived from either hemp or marijuana. THC--a psychoactive compound--is found at high levels in marijuana and low levels in hemp."

Report Number:
CRS In Focus, IF11250
Author:
Publisher:
Date:
2020-02-10
Copyright:
Public Domain
Retrieved From:
Congressional Research Service: https://crsreports.congress.gov/
Format:
pdf
Media Type:
application/pdf
URL:
Help with citations